ROAD MAP

Cancerappy: Using AI to Advance Cancer Research

Since 2019, Cancerappy has been harnessing the power of artificial intelligence to transform cancer research, from improving detection and diagnosis to developing more effective treatments with fewer side effects. We’re putting AI to work in areas like genomics,...
Read More

Cancerappy at #Bventure24

We’re back at Bventure! Cancerappy is actively participating in this innovation event through the University of Deusto, joining the roundtable discussion, “The Value of Talent in an AI Startup.” On Tuesday, Oct 15th, our CEO will share insights on how AI is impacting...
Read More

CancerAppy to Speak at ACCESS CHINA Partnering Forum

We are glad to announce that Luis Martin, the Chief Executive Officer of CancerAppy, will be presenting at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase during September 24th to 25th, and 27th, 2024. ACCESS CHINA Biotech Forum is the largest corporate...
Read More

China health innovation ecosystem

A Cancerappy delegation has participated in a roadshow of European companies to learn about the innovative health ecosystem in the Shanghai and Wuxi area. Our CEO has had the opportunity to hold various meetings with different agents of the innovation ecosystem,...
Read More

Named as one of the Top Ten Drug Discovery

Read More

CancerAppy Contributes to Innovative Scientific Paper on ADCs in Clinical Use

CancerAppy pioneers in ADC research, contributing to a transformative scientific paper. Our team's dedication unveils insights on payload properties, shaping the future of ADC therapies. A crucial leap in cancer treatment. We are proud to announce our significant...
Read More

CancerAppy at ESMO Congress: Pioneering Research Unveiled!

CancerAppy's groundbreaking study at ESMO Congress (Oct '23) reveals profound insights into Treg impact on tumor immune responses. Unearthing common transcripts and potential predictors, our AI-driven research shapes the future of cancer treatment.CancerAppy has...
Read More

Milestone Achieved: CancerAppy’s First Collaborative Research Paper Unveiled

We are delighted to announce our first collaborative scientific research article. At CancerAppy, our commitment to harnessing the power of AI in cancer drug discovery has led us to join forces with leading researchers in the field. This groundbreaking collaboration...
Read More

BIO Spain

We're excited to be part of BioSpain 2023, and despite our packed schedule, we welcome you to connect with us at the BasqueHealthCluster booth. Explore our groundbreaking work in the world of biotechnology and cancer research. See you there!. More about BIO Spain
Read More

ATG symbio Spain

Cancerappy participated in the II international congress organized by ATG Symbio Spain that was held inBarcelona at the Biomedical Research Park (PRBB) on July 1 and 2, 2023.Our CEO had the opportunity to present our company and show our latest advances in the NMEs...
Read More

2023

2022

CA05 Lead Identification

Jul 21, 2022 | ,

We have identified insilico, several compounds as inhibitors of CA05, which is a protein kinase overexpressed in various types of tumors with a clear oncogenic role and no type-specific inhibitor, and we have started in vitro trials to select a lead.

CA02/03 Target Identification vs NSCLC

Jan 21, 2022 | ,

CancerAppy has identified two membrane proteins that are upregulated in NSCLC and has patented their use as targets to vectorize compounds against these tumors, or as surrogates for immune activation, to select patients o explore combinations with new immune therapies

2021

4YFN 2021

Jun 11, 2021 |

Cancerappy has been selected to participate in the Espacio España 4YFN 2021.  

2020

2019